U.S., March 27 -- ClinicalTrials.gov registry received information related to the study (NCT06895967) titled 'A Study of TAK-881 and HyQvia in Healthy Adults' on March 20.
Brief Summary: The main aim of this study is to understand how the body absorbs, processes, and removes (known as pharmacokinetics or PK) TAK-881 and HyQvia, after they are given as a single injection under the skin in healthy adults.
Study participants will receive a single dose of TAK-881 or HyQvia on Day 1.
During the study, participants will need to stay at the clinic for 8 days followed by 8 ambulatory follow up visits till Day 85.
Study Start Date: March 24
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteers
Intervention:
BIOLOGICAL: TAK-881
Participa...